[go: up one dir, main page]

BRPI0613303A2 - método de separação e conjunto para correntes de processo em unidades de separação de componentes - Google Patents

método de separação e conjunto para correntes de processo em unidades de separação de componentes

Info

Publication number
BRPI0613303A2
BRPI0613303A2 BRPI0613303-7A BRPI0613303A BRPI0613303A2 BR PI0613303 A2 BRPI0613303 A2 BR PI0613303A2 BR PI0613303 A BRPI0613303 A BR PI0613303A BR PI0613303 A2 BRPI0613303 A2 BR PI0613303A2
Authority
BR
Brazil
Prior art keywords
process streams
component
separation
assembly
assembly method
Prior art date
Application number
BRPI0613303-7A
Other languages
English (en)
Inventor
J Wurtman
Ingrid Richardson
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0613303(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of BRPI0613303A2 publication Critical patent/BRPI0613303A2/pt
Publication of BRPI0613303A8 publication Critical patent/BRPI0613303A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fertilizers (AREA)
  • Separation, Recovery Or Treatment Of Waste Materials Containing Plastics (AREA)
  • Carbon And Carbon Compounds (AREA)

Abstract

MéTODO DE SEPARAçãO E CONJUNTO PARA CORRENTES DE PROCESSO EM UNIDADES DE SEPARAçãO DE COMPONENTES. Trata-se de um método e um conjunto para a utilização de material sólido celular de células abertas em uma unidade de separação de componentes para separar uma ou mais correntes de processo em correntes de processo de componentes têm composições desejadas. Um método e um conjunto para a utilização do dito material sólido celular de células abertas para separar correntes de processo em correntes de processo de componentes desejadas em uma unidade de separação de componentes, em que o material sólido celular de células abertas pode incluir óxidos, carbetos, nitretos, boretos, cerâmica, metais, polímeros, e materiais de deposição de vapor químico.
BRPI0613303A 2005-05-23 2006-05-23 composições que contêm pufa e/ou uridina e métodos de uso das mesmas BRPI0613303A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68335205P 2005-05-23 2005-05-23
US71607705P 2005-09-13 2005-09-13
US75505806P 2006-01-03 2006-01-03
US76175306P 2006-01-25 2006-01-25
PCT/US2006/019778 WO2006127627A2 (en) 2005-05-23 2006-05-23 Compostions containing pufa and/or uridine and methods of use thereof

Publications (2)

Publication Number Publication Date
BRPI0613303A2 true BRPI0613303A2 (pt) 2009-08-04
BRPI0613303A8 BRPI0613303A8 (pt) 2018-01-30

Family

ID=37452701

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0613274-0A BRPI0613274A2 (pt) 2005-05-23 2006-05-23 composições que contêm pufa e métodos de uso das mesmas
BRPI0613303A BRPI0613303A8 (pt) 2005-05-23 2006-05-23 composições que contêm pufa e/ou uridina e métodos de uso das mesmas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0613274-0A BRPI0613274A2 (pt) 2005-05-23 2006-05-23 composições que contêm pufa e métodos de uso das mesmas

Country Status (15)

Country Link
US (3) US10086009B2 (pt)
EP (3) EP1909801B2 (pt)
JP (3) JP5566604B2 (pt)
CN (1) CN105663151A (pt)
AU (2) AU2006251569B2 (pt)
BR (2) BRPI0613274A2 (pt)
CA (2) CA2645647C (pt)
DK (1) DK1888081T3 (pt)
ES (2) ES2615521T3 (pt)
HU (1) HUE031206T2 (pt)
NZ (3) NZ600740A (pt)
PL (1) PL1888081T3 (pt)
PT (1) PT1888081T (pt)
RU (1) RU2603470C2 (pt)
WO (2) WO2006127620A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
WO2004050023A2 (en) * 2002-11-27 2004-06-17 Dmi Biosciences, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
US10086009B2 (en) 2005-05-23 2018-10-02 Massachusetts Institute Of Technologies Compositions containing pufa and/or uridine and methods of use thereof
MX336435B (es) * 2005-07-08 2016-01-19 Dsm Ip Assets Bv Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.
EP1951308B1 (de) * 2005-11-25 2013-02-20 Gisela Susilo Kombinationspräparate enthaltend physiologische zellmembran-bestandteile, einschliesslich phosphatidylserin, cholin und ein pyrimidinnukleos/tid
KR20090097945A (ko) * 2006-12-28 2009-09-16 메이지 데어리즈 코포레이션 젖 유래 인지질을 함유하는 유유아 뇌발달 촉진제 및 그것을 함유하는 식품 조성물
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002148A1 (en) 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
CA2692309C (en) * 2007-06-26 2016-08-16 N.V. Nutricia Improving memory in subjects with mini-mental state examination of 24-26
WO2009002146A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009059306A1 (en) * 2007-11-02 2009-05-07 Massachusetts Institute Of Technology Uridine dietary supplementation compliance methods and use thereof
WO2009057994A1 (en) * 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
ES2411726T3 (es) 2007-12-20 2013-07-08 N.V. Nutricia Producto líquido que contiene nucleótidos/nucleósidos
EP2391361A1 (en) * 2009-02-02 2011-12-07 Martek Biosciences Corporation Methods for improving cognitive function and decreasing heart rate
WO2011133580A1 (en) * 2010-04-19 2011-10-27 Back Bay Scientific Llc Use of drugs that activate p2y receptors to enhance synaptogenesis
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
JP2015501426A (ja) * 2011-10-21 2015-01-15 オムセラ・ファーマシューティカルズ・インコーポレイテッド 注意欠陥多動障害を処置するまたは予防する方法および組成物
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013129914A1 (en) * 2012-03-02 2013-09-06 N.V. Nutricia Method for improving functional synaptic connectivity
US20150044138A1 (en) * 2012-03-02 2015-02-12 N.V. Nutricia Method for improving functional synaptic connectivity
WO2014171813A1 (en) 2013-04-17 2014-10-23 N.V. Nutricia Nutritional composition for improving brain function in phenylketonuria
CN103877144B (zh) * 2013-05-02 2017-02-22 杭州耐奇睿生物医药科技有限公司 花生衣活性组分的应用及包含该花生衣活性组分的组合物
WO2015138879A1 (en) * 2014-03-13 2015-09-17 Massachusetts Institute Of Technology Compositions containing pufa, uridine and choline and methods of use thereof
WO2016083362A1 (en) * 2014-11-25 2016-06-02 Fonden For Helene Elsass Centeret Composition for improving cognitive functions
WO2017069613A1 (en) 2015-10-23 2017-04-27 N.V. Nutricia Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
WO2017155387A1 (en) * 2016-03-08 2017-09-14 N.V. Nutricia Method for supporting memory function and/or cognitive function
SG11201803022TA (en) * 2016-03-30 2018-05-30 Nestec Sa Compositions comprising fatty acids and their use
CA3029005A1 (en) 2016-06-27 2018-01-04 Ohio State Innovation Foundation Liponucleotide-based therapy for ards
MX391435B (es) * 2016-09-29 2025-03-21 Soc Des Produits Nestle S A Star Acidos grasos omega 3 y colina como neuroprotectores en pacientes sin demencia.
WO2018108976A1 (en) * 2016-12-13 2018-06-21 Dsm Ip Assets B.V. Pufa salt formulations (ii)
WO2021231566A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology The use of choline supplementation as therapy for apoe4-related disorders
EP4190319A4 (en) 2020-07-29 2024-05-01 Novamedica Limited Liability Company Pharmaceutical composition comprising memantine and citicoline
EP4353261A4 (en) * 2021-06-09 2025-06-18 Hospital Sant Joan de Deu Nutraceutical combination and its use in the treatment of neurological diseases
CN113577092B (zh) * 2021-07-30 2022-07-01 陈玉松 一种延缓衰老的含核苷酸的组合物及其制备方法和应用
CN115774059A (zh) * 2021-09-07 2023-03-10 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物及其筛选方法和应用
TR2021016704A2 (tr) * 2021-10-26 2021-11-22 Bursa Uludag Ueniversitesi Üri̇di̇ni̇n ön uyaran aracili i̇nhi̇bi̇syon bozukluğu i̇le seyreden hastaliklarin tedavi̇si̇nde kullanimi
WO2023150389A1 (en) * 2022-02-07 2023-08-10 Cornell University Compositions and methods for increasing dha availability
CN115334384B (zh) 2022-08-05 2025-03-14 立臻科技(昆山)有限公司 一种移动终端会议音箱
CN119881117A (zh) * 2023-10-25 2025-04-25 中国科学院上海营养与健康研究所 母乳芥酸检测在评价婴幼儿发育中的用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
US20050027004A1 (en) 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
JPH08511533A (ja) * 1993-06-09 1996-12-03 マーテック・バイオサイエンスィズ・コーポレーション 神経学的障害の治療に有用な方法および医薬用組成物
US5492899A (en) * 1994-01-10 1996-02-20 Abbott Laboratories Infant nutritional formula with ribo-nucleotides
JPH07143862A (ja) 1994-05-06 1995-06-06 Maruha Corp 脳機能改善効果を有する機能性食品。
IL122405A (en) * 1995-06-07 2003-04-10 Martek Biosciences Corp Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
JPH0975000A (ja) 1995-07-07 1997-03-25 Nisshin Oil Mills Ltd:The 母子栄養用油脂含有飲食物
US6200624B1 (en) 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
DE19608137A1 (de) * 1996-03-02 1997-09-04 Meyer Lucas Gmbh & Co Lipid-Zubereitungen für diätetische Zwecke
JP3627043B2 (ja) 1996-04-24 2005-03-09 明治乳業株式会社 ｎ−６系列／ｎ−３系列脂肪酸バランス 改善ヌクレオチド含有乳児用食品
ATE347607T1 (de) * 1996-07-23 2006-12-15 Nagase Chemtex Corp Verfahren zur herstellung von decosahexaensäure und decosapentsäure
PL343902A1 (en) 1997-02-21 2001-09-10 Abbott Lab Methods of and compositions for reducing enteritis and colitis morbidity rate
US6080787A (en) 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
JPH10327804A (ja) 1997-06-04 1998-12-15 Meiji Milk Prod Co Ltd 核酸関連物質、ｄｈａ、アラキドン酸及び コレステロール含有栄養組成物
JP3731983B2 (ja) 1997-08-27 2006-01-05 明治製菓株式会社 痴呆犬の夜鳴き改善薬
JP3408958B2 (ja) * 1997-10-24 2003-05-19 旭化成株式会社 魚介類由来の有用物質を含む組成物およびその有用物質の製造方法
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US7413759B2 (en) 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
EP2145627B1 (en) 1998-07-31 2014-04-16 Massachusetts Institute Of Technology Use of uridine in combination with choline for the treatment of mood and emotional disorders
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US20050203053A1 (en) † 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
WO2000012102A1 (en) 1998-08-31 2000-03-09 Proteotech, Inc. Blended compositions for treatment of alzheimer's disease and other amyloidoses
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6596302B2 (en) 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
CA2344564C (en) 2000-09-14 2008-07-22 General Electric Canada Inc. Graded electric field insulation system for dynamoelectric machine
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US6541043B2 (en) 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
EP1302196A1 (de) 2001-10-16 2003-04-16 Habinger, René, Ing. Mag. Intelligenzfördernde Zahncreme
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US6677470B2 (en) 2001-11-20 2004-01-13 Natural Asa Functional acylglycerides
US20030114415A1 (en) 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
US20040048926A1 (en) 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
US20060057185A1 (en) 2002-09-24 2006-03-16 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
JP2004231585A (ja) 2002-12-05 2004-08-19 Fancl Corp 生体内ホモシステインレベル低減用および上昇抑制用組成物
EP1589979A4 (en) * 2002-12-20 2009-04-01 Mclean Hospital Corp CONNECTIONS FOR NORMALIZING THE SLEEP / WAKE-UP CYCLE
CN1203867C (zh) 2003-03-11 2005-06-01 刘威 精制海狗油在制备防治老年痴呆药中的应用
US7951410B2 (en) 2003-04-14 2011-05-31 Mead Johnson Nutrition Company Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid
US7867541B2 (en) 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
CN100438777C (zh) 2003-09-26 2008-12-03 雀巢技术公司 含有不饱和脂肪酸和微量元素的营养组合物
US8921422B2 (en) 2003-10-01 2014-12-30 The Iams Company Methods and kits for enhancing ability to learn in a puppy or kitten
WO2005086619A2 (en) 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1656839A1 (en) 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
US20060247153A1 (en) 2005-04-29 2006-11-02 Mcmahon Robert J Method of improving learning and memory in mammals
US10086009B2 (en) * 2005-05-23 2018-10-02 Massachusetts Institute Of Technologies Compositions containing pufa and/or uridine and methods of use thereof
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein

Also Published As

Publication number Publication date
DK1888081T3 (en) 2017-02-27
EP1909801B1 (en) 2016-12-28
US20190167705A1 (en) 2019-06-06
RU2011120440A (ru) 2012-11-27
AU2006251562B2 (en) 2012-03-22
NZ600740A (en) 2014-02-28
US10525071B2 (en) 2020-01-07
US10736912B2 (en) 2020-08-11
EP1909801A2 (en) 2008-04-16
PL1888081T3 (pl) 2017-07-31
WO2006127620A3 (en) 2009-05-07
HUE031206T2 (en) 2017-06-28
CN105663151A (zh) 2016-06-15
JP2014133767A (ja) 2014-07-24
EP1909801B2 (en) 2020-03-18
EP1888081A2 (en) 2008-02-20
CA2645645A1 (en) 2006-11-30
CA2645645C (en) 2015-07-14
AU2006251569A1 (en) 2006-11-30
NZ563660A (en) 2012-11-30
WO2006127627A2 (en) 2006-11-30
BRPI0613274A2 (pt) 2009-08-04
WO2006127620A2 (en) 2006-11-30
RU2603470C2 (ru) 2016-11-27
EP1888081B1 (en) 2016-12-28
ES2624702T5 (es) 2020-12-11
BRPI0613303A8 (pt) 2018-01-30
EP3090740A1 (en) 2016-11-09
US20100099645A1 (en) 2010-04-22
CA2645647A1 (en) 2006-11-30
JP2008542280A (ja) 2008-11-27
JP5566604B2 (ja) 2014-08-06
JP5566603B2 (ja) 2014-08-06
NZ563659A (en) 2011-05-27
US20100022567A1 (en) 2010-01-28
JP5823564B2 (ja) 2015-11-25
CA2645647C (en) 2016-07-12
PT1888081T (pt) 2017-03-01
AU2006251569B2 (en) 2012-06-21
US10086009B2 (en) 2018-10-02
ES2615521T3 (es) 2017-06-07
ES2624702T3 (es) 2017-07-17
AU2006251562A1 (en) 2006-11-30
EP1888081A4 (en) 2012-12-05
JP2008545693A (ja) 2008-12-18
WO2006127627A3 (en) 2009-04-16
EP1909801A4 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
BRPI0613303A2 (pt) método de separação e conjunto para correntes de processo em unidades de separação de componentes
MY146267A (en) Separation method and assembly for process streams in component separation units
UA92486C2 (ru) Система покрытия пола
WO2007073484A3 (en) Methods and systems for conducting research operations
BRPI0815409A2 (pt) Cepa bacteriana, processos para a produção fermentativa de um composto, e para a produção de um composto, e, uso de uma cepa bacteriana.
EP1972017B8 (en) Organic/ inorganic composite separator having morphology gradient, manufacturing method thereof and electrochemical device containing the same
NL2000050A1 (nl) Systemen, methoden en katalysatoren voor het produceren van een ruwe-oliehoudend product.
BRPI0508734A (pt) membrana, folha compósita, processos e processo para a formação de um material
ATE435506T1 (de) Konjugierte polymere, deren darstellung und verwendung
BRPI0807669A2 (pt) Processo para produzir um produto de cumento tendo uma pureza de pelo menos 99,50 por cento
CL2007002888A1 (es) Compuestos derivados de n-metansulfonilamino amidas, inhibidores de metaloproteasas de matriz; composicion farmaceutica; y uso para el tratamiento de un trastorno de proliferacion celular.
WO2007056250A3 (en) Heterogeneous assay of analytes in solution using polymers
WO2004045494A3 (en) Biological glue based on thrombin-conjugated nanoparticles
WO2008095165A3 (en) Cell co-culture systems and uses thereof
CL2008000362A1 (es) Mezcla pesticida que comprende un compuesto fenilsemicarbazona y clotianidina; composicion pesticida que la comprende; proceso para preparar la composicion; metodo para controlar insectos, aracnidos o nematodos y su uso.
BRPI0719706A2 (pt) Processo para a preparação do 1,3-propanodiol.
MY145888A (en) Hydrocarbon conversion process including a staggered-bypass reaction system
BRPI0817040A2 (pt) Processo para produção de compostos orgânicos de baixo peso molecular de materiais carbonáceos.
BRPI0916903A2 (pt) Compostos líquidos e sua utilização, material técnico e método para a proteção de materiais técnicos contra infestação e/ou destruição por meio de microorganismos, aplicação de noit, ipbc e solventes e ....
BRPI0718635A2 (pt) Método para a densificação de substratos porosos com o uso de inflitração por vapor químico ("cvi") em um forno cvi.
ZA200805382B (en) Keratin-binding effector molecules, and method for the production thereof
WO2006127706A3 (en) Method and system of configuring media units
GB0800340D0 (en) Pyrolysis system
EP1950258A4 (en) ORGANIC-INORGANIC COMPOUND POWDER, METHOD OF MANUFACTURING THEREOF AND COMPOSITION COMPRISING THE POWDER
WO2008051271A3 (en) Thin sheet for retaining biomolecules

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: APRESENTE O DEPOSITANTE O RELATORIO DESCRITIVO E OS DESENHOS DO PEDIDO, CONFORME DETERMINA O ATO NORMATIVO NO 128 DE 05/03/1997, ITENS 9.2 E 9.2.1.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]